Acadia Pharmaceuticals ACAD Accrued investment income
Accrued investment income at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestReceivableCurrent.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's accrued investment income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's accrued investment income?
- Acadia Pharmaceuticals (ACAD) reported accrued investment income of $13.03M in Q1 2026.
- How has Acadia Pharmaceuticals's accrued investment income changed year-over-year?
- Acadia Pharmaceuticals's accrued investment income increased by 63.5% year-over-year, from $7.97M to $13.03M.
- What is the long-term trend for Acadia Pharmaceuticals's accrued investment income?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's accrued investment income has grown at a 67.4% compound annual growth rate (CAGR), from $2.04M to $26.77M.
- What does accrued investment income mean?
- This metric represents the interest, dividends, or other investment-related income that has been earned by the company but has not yet been collected in cash as of the balance sheet date. It reflects the accrual of returns on the company's cash equivalents and marketable securities portfolio. Monitoring this balance provides insight into the yield generated by the company's treasury management activities.